schliessen

Filtern

 

Bibliotheken

Preparation and Evaluation of Oxaliplatin Thermosensitive Liposomes with Rapid Release and High Stability

Oxaliplatin (OXP) was reported to show low anti-tumor activity when used alone and to display side effects; this low activity was attributed to high partitioning to erythrocytes and low accumulation in tumors. Thermosensitive liposomes (TSL) were considered able to specifically deliver drugs to heat... Full description

Journal Title: PLoS ONE 01 January 2016, Vol.11(7), p.e0158517
Main Author: Chunying Zeng
Other Authors: Fanglin Yu , Yang Yang , Xiaohui Cheng , Yan Liu , Hui Zhang , Shiqing Zhao , Zhenbo Yang , Mingyuan Li , Zhiping Li , Xingguo Mei
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: E-ISSN: 1932-6203 ; DOI: 10.1371/journal.pone.0158517
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: doaj_soai_doaj_org_article_73214baaa10d427984f75bb6971d44b2
title: Preparation and Evaluation of Oxaliplatin Thermosensitive Liposomes with Rapid Release and High Stability
format: Article
creator:
  • Chunying Zeng
  • Fanglin Yu
  • Yang Yang
  • Xiaohui Cheng
  • Yan Liu
  • Hui Zhang
  • Shiqing Zhao
  • Zhenbo Yang
  • Mingyuan Li
  • Zhiping Li
  • Xingguo Mei
subjects:
  • Sciences (General)
ispartof: PLoS ONE, 01 January 2016, Vol.11(7), p.e0158517
description: Oxaliplatin (OXP) was reported to show low anti-tumor activity when used alone and to display side effects; this low activity was attributed to high partitioning to erythrocytes and low accumulation in tumors. Thermosensitive liposomes (TSL) were considered able to specifically deliver drugs to heated tumors and to resolve the OXP distribution problem. Regretfully, TSL encapsulating doxorubicin did not demonstrate significant improvement in progression-free survival. Drug release below 41°C and significant leakage were considered major reasons for the failure. The purpose of this study was to acquire OXP TSL with rapid release at the triggered temperature and high stability at body temperature and at storage temperatures. A small quantity of poloxamer 188 was introduced into the TSL formulation to stabilize the encapsulated drug. It was shown that the addition of poloxamer 188 had no influence on the TSL characteristics. More than 90% of OXP was released within 10 min at 42°C, and less than 15% was released within 60 min at temperatures below 39°C. TSL were stable at 37°C for 96 h and at 4°C for 6 months. The anti-tumor activity of TSL at the dose of 2.5 mg/kg was certified to be equal to those of OXP injection and non-thermosensitive liposomes (NTSL) at the dose of 5 mg/kg, and significant improvement of tumor inhibition was observed in TSL compared with injection and NTSL at the same dose. It was also shown from the histological transmutation of tumors that TSL had stronger anti-tumor activity. Therefore, it could be concluded that TSL composed of a proper amount of poloxamer had rapid release and high stability, and OXP TSL would be anticipated to exert prominent anti-tumor activity in the clinic.
language: eng
source:
identifier: E-ISSN: 1932-6203 ; DOI: 10.1371/journal.pone.0158517
fulltext: fulltext_linktorsrc
issn:
  • 1932-6203
  • 19326203
url: Link


@attributes
ID15808861
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordidoai_doaj_org_article_73214baaa10d427984f75bb6971d44b2
sourceiddoaj_s
recordidTN_doaj_soai_doaj_org_article_73214baaa10d427984f75bb6971d44b2
sourcesystemOther
dbidDOA
pqid1808702876
galeid458087699
display
typearticle
titlePreparation and Evaluation of Oxaliplatin Thermosensitive Liposomes with Rapid Release and High Stability
creatorChunying Zeng ; Fanglin Yu ; Yang Yang ; Xiaohui Cheng ; Yan Liu ; Hui Zhang ; Shiqing Zhao ; Zhenbo Yang ; Mingyuan Li ; Zhiping Li ; Xingguo Mei
ispartofPLoS ONE, 01 January 2016, Vol.11(7), p.e0158517
identifierE-ISSN: 1932-6203 ; DOI: 10.1371/journal.pone.0158517
subjectSciences (General)
descriptionOxaliplatin (OXP) was reported to show low anti-tumor activity when used alone and to display side effects; this low activity was attributed to high partitioning to erythrocytes and low accumulation in tumors. Thermosensitive liposomes (TSL) were considered able to specifically deliver drugs to heated tumors and to resolve the OXP distribution problem. Regretfully, TSL encapsulating doxorubicin did not demonstrate significant improvement in progression-free survival. Drug release below 41°C and significant leakage were considered major reasons for the failure. The purpose of this study was to acquire OXP TSL with rapid release at the triggered temperature and high stability at body temperature and at storage temperatures. A small quantity of poloxamer 188 was introduced into the TSL formulation to stabilize the encapsulated drug. It was shown that the addition of poloxamer 188 had no influence on the TSL characteristics. More than 90% of OXP was released within 10 min at 42°C, and less than 15% was released within 60 min at temperatures below 39°C. TSL were stable at 37°C for 96 h and at 4°C for 6 months. The anti-tumor activity of TSL at the dose of 2.5 mg/kg was certified to be equal to those of OXP injection and non-thermosensitive liposomes (NTSL) at the dose of 5 mg/kg, and significant improvement of tumor inhibition was observed in TSL compared with injection and NTSL at the same dose. It was also shown from the histological transmutation of tumors that TSL had stronger anti-tumor activity. Therefore, it could be concluded that TSL composed of a proper amount of poloxamer had rapid release and high stability, and OXP TSL would be anticipated to exert prominent anti-tumor activity in the clinic.
languageeng
oafree_for_read
source
version9
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
linktorsrc$$Uhttps://doaj.org/article/73214baaa10d427984f75bb6971d44b2$$EView_full_text_in_DOAJ
search
creatorcontrib
0Chunying Zeng
1Fanglin Yu
2Yang Yang
3Xiaohui Cheng
4Yan Liu
5Hui Zhang
6Shiqing Zhao
7Zhenbo Yang
8Mingyuan Li
9Zhiping Li
10Xingguo Mei
titlePreparation and Evaluation of Oxaliplatin Thermosensitive Liposomes with Rapid Release and High Stability
description

Oxaliplatin (OXP) was reported to show low anti-tumor activity when used alone and to display side effects; this low activity was attributed to high partitioning to erythrocytes and low accumulation in tumors. Thermosensitive liposomes (TSL) were considered able to specifically deliver drugs to heated tumors and to resolve the OXP distribution problem. Regretfully, TSL encapsulating doxorubicin did not demonstrate significant improvement in progression-free survival. Drug release below 41°C and significant leakage were considered major reasons for the failure. The purpose of this study was to acquire OXP TSL with rapid release at the triggered temperature and high stability at body temperature and at storage temperatures. A small quantity of poloxamer 188 was introduced into the TSL formulation to stabilize the encapsulated drug. It was shown that the addition of poloxamer 188 had no influence on the TSL characteristics. More than 90% of OXP was released within 10 min at 42°C, and less than 15% was released within 60 min at temperatures below 39°C. TSL were stable at 37°C for 96 h and at 4°C for 6 months. The anti-tumor activity of TSL at the dose of 2.5 mg/kg was certified to be equal to those of OXP injection and non-thermosensitive liposomes (NTSL) at the dose of 5 mg/kg, and significant improvement of tumor inhibition was observed in TSL compared with injection and NTSL at the same dose. It was also shown from the histological transmutation of tumors that TSL had stronger anti-tumor activity. Therefore, it could be concluded that TSL composed of a proper amount of poloxamer had rapid release and high stability, and OXP TSL would be anticipated to exert prominent anti-tumor activity in the clinic.

subjectSciences (General)
general
0English
1Public Library of Science (PLoS)
210.1371/journal.pone.0158517
3Directory of Open Access Journals (DOAJ)
sourceiddoaj_s
recordiddoaj_soai_doaj_org_article_73214baaa10d427984f75bb6971d44b2
issn
01932-6203
119326203
rsrctypearticle
creationdate2016
addtitlePLoS ONE
searchscope
0doaj_full
1doaj1
scope
0doaj_full
1doaj1
lsr45$$EView_full_text_in_DOAJ
tmp01Directory of Open Access Journals (DOAJ)
tmp02DOA
startdate20160101
enddate20160101
lsr40PLoS ONE, 01 January 2016, Vol.11 (7), p.e0158517
doi10.1371/journal.pone.0158517
citationpf e0158517 vol 11 issue 7
lsr30VSR-Enriched:[pqid, pages, galeid]
sort
titlePreparation and Evaluation of Oxaliplatin Thermosensitive Liposomes with Rapid Release and High Stability
authorChunying Zeng ; Fanglin Yu ; Yang Yang ; Xiaohui Cheng ; Yan Liu ; Hui Zhang ; Shiqing Zhao ; Zhenbo Yang ; Mingyuan Li ; Zhiping Li ; Xingguo Mei
creationdate20160101
lso0120160101
facets
frbrgroupid3874168477739935404
frbrtype5
newrecords20190714
languageeng
topicSciences (General)
collectionDirectory of Open Access Journals (DOAJ)
prefilterarticles
rsrctypearticles
creatorcontrib
0Chunying Zeng
1Fanglin Yu
2Yang Yang
3Xiaohui Cheng
4Yan Liu
5Hui Zhang
6Shiqing Zhao
7Zhenbo Yang
8Mingyuan Li
9Zhiping Li
10Xingguo Mei
jtitlePLoS ONE
creationdate2016
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext_linktorsrc
addata
au
0Chunying Zeng
1Fanglin Yu
2Yang Yang
3Xiaohui Cheng
4Yan Liu
5Hui Zhang
6Shiqing Zhao
7Zhenbo Yang
8Mingyuan Li
9Zhiping Li
10Xingguo Mei
atitlePreparation and Evaluation of Oxaliplatin Thermosensitive Liposomes with Rapid Release and High Stability
jtitlePLoS ONE
risdate20160101
volume11
issue7
spagee0158517
eissn1932-6203
formatjournal
genrearticle
ristypeJOUR
abstract

Oxaliplatin (OXP) was reported to show low anti-tumor activity when used alone and to display side effects; this low activity was attributed to high partitioning to erythrocytes and low accumulation in tumors. Thermosensitive liposomes (TSL) were considered able to specifically deliver drugs to heated tumors and to resolve the OXP distribution problem. Regretfully, TSL encapsulating doxorubicin did not demonstrate significant improvement in progression-free survival. Drug release below 41°C and significant leakage were considered major reasons for the failure. The purpose of this study was to acquire OXP TSL with rapid release at the triggered temperature and high stability at body temperature and at storage temperatures. A small quantity of poloxamer 188 was introduced into the TSL formulation to stabilize the encapsulated drug. It was shown that the addition of poloxamer 188 had no influence on the TSL characteristics. More than 90% of OXP was released within 10 min at 42°C, and less than 15% was released within 60 min at temperatures below 39°C. TSL were stable at 37°C for 96 h and at 4°C for 6 months. The anti-tumor activity of TSL at the dose of 2.5 mg/kg was certified to be equal to those of OXP injection and non-thermosensitive liposomes (NTSL) at the dose of 5 mg/kg, and significant improvement of tumor inhibition was observed in TSL compared with injection and NTSL at the same dose. It was also shown from the histological transmutation of tumors that TSL had stronger anti-tumor activity. Therefore, it could be concluded that TSL composed of a proper amount of poloxamer had rapid release and high stability, and OXP TSL would be anticipated to exert prominent anti-tumor activity in the clinic.

pubPublic Library of Science (PLoS)
doi10.1371/journal.pone.0158517
urlhttps://doaj.org/article/73214baaa10d427984f75bb6971d44b2
lad01PLoS ONE
oafree_for_read
pagese0158517
date2016-01-01